🇺🇸 FDA
Patent

US 10112956

Heterocyclic compounds having cholesterol 24-hydroxylase activity

granted A61KA61K9/2018A61K9/4858

Quick answer

US patent 10112956 (Heterocyclic compounds having cholesterol 24-hydroxylase activity) held by Takeda Pharmaceutical Company Limited expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K9/2018, A61K9/4858, A61P, A61P25/00